Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Emergent Biosolutions Inc's Business Segments
Emergent Biosolutions Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
2
Largest Segment
MCM Products
Total Revenue
$ 156
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- MCM Products65.2%
- Commercial Products27.5%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| MCM Products | $ 102 | 65.2% |
| Commercial Products | $ 43 | 27.5% |
Revenue by Product & Service Category - Q1 FY2026
- Product and Service95.9%
- Medical Countermeasures (mcm) Product40.8%
- All other revenue4.1%
- Contracts and grants4.1%
- Commercial Product0.4%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product and Service | $ 150 | 95.9% |
| Medical Countermeasures (mcm) Product | $ 64 | 40.8% |
| All other revenue | $ 6 | 4.1% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
2 more categories available
Sign in to unlock the full Emergent Biosolutions Inc dataset.
Description of Emergent Biosolutions Inc
Emergent BioSolutions Inc. is a publicly traded biotechnology company headquartered in Gaithersburg, Maryland, USA. The company specializes in the development, manufacturing, and commercialization of vaccines and immunotherapies for infectious diseases and biodefense.
Founded in 1998, Emergent BioSolutions has grown to become a leading provider of medical countermeasures to governments, militaries, and private organizations around the world. The company's portfolio of products includes vaccines for anthrax, smallpox, and typhoid fever, as well as treatments for botulism and nerve agents.
Emergent BioSolutions operates a state-of-the-art manufacturing facility in Baltimore, Maryland, which has the capacity to produce millions of vaccine doses per year. The facility is equipped with advanced technologies and processes to ensure the highest levels of quality and safety.
The company has a strong focus on research and development, with dedicated teams working on the discovery and development of new vaccines and therapies. Emergent BioSolutions also partners with leading academic and research institutions to accelerate the development of breakthrough treatments.
In addition to its biodefense work, Emergent BioSolutions is actively involved in developing treatments for infectious diseases such as COVID-19. The company has partnered with other biotech firms and government agencies to develop potential treatments and vaccines for the virus.
Overall, Emergent BioSolutions Inc. is a dynamic and innovative biotech company that is dedicated to improving public health and safety through the development and manufacturing of life-saving vaccines and therapies.
Founded in 1998, Emergent BioSolutions has grown to become a leading provider of medical countermeasures to governments, militaries, and private organizations around the world. The company's portfolio of products includes vaccines for anthrax, smallpox, and typhoid fever, as well as treatments for botulism and nerve agents.
Emergent BioSolutions operates a state-of-the-art manufacturing facility in Baltimore, Maryland, which has the capacity to produce millions of vaccine doses per year. The facility is equipped with advanced technologies and processes to ensure the highest levels of quality and safety.
The company has a strong focus on research and development, with dedicated teams working on the discovery and development of new vaccines and therapies. Emergent BioSolutions also partners with leading academic and research institutions to accelerate the development of breakthrough treatments.
In addition to its biodefense work, Emergent BioSolutions is actively involved in developing treatments for infectious diseases such as COVID-19. The company has partnered with other biotech firms and government agencies to develop potential treatments and vaccines for the virus.
Overall, Emergent BioSolutions Inc. is a dynamic and innovative biotech company that is dedicated to improving public health and safety through the development and manufacturing of life-saving vaccines and therapies.
Emergent Biosolutions Inc. is a global life sciences company that is deeply committed to addressing public health needs through the development and manufacturing of innovative medical solutions. The company operates across several key segments, each focused on critical areas that influence public health and safety. Below is an extensive overview of the companys segments, products, and services:
Segments
1. Biodefense:
- Emergents biodefense segment is integral in developing and deploying medical countermeasures against biological and chemical threats. This includes the advanced manufacturing and commercialization of critical vaccines and therapeutics.
- A highlight of this segment is BioThrax, the only FDA-approved vaccine for the prevention of anthrax, specifically recognized for its pivotal role in protecting the U.S. population from potential bioterrorism threats. The company also collaborates closely with government entities to ensure readiness against emerging biological threats, including collaborations under the Biomedical Advanced Research and Development Authority (BARDA) umbrella.
2. Infectious Diseases:
- This segment focuses on vaccines and treatments for various infectious diseases. Emergent Biosolutions has made significant strides in addressing public health challenges such as the Zika virus, dengue fever, Ebola virus disease, and the recent COVID-19 pandemic.
- Notable products in this domain include ACAM2000, an FDA-approved vaccine for smallpox, and ongoing efforts to develop a vaccine for COVID-19.
- In addition, the companys portfolio under development may include therapies targeting innovative solutions for pandemic and endemic infectious diseases.
3. Oncology:
- In the oncology segment, Emergent Biosolutions is dedicated to creating novel immunotherapies aimed at harnessing the body’s immune system to combat cancer effectively. The struggles against melanoma and non-small cell lung cancer are primary targets for the company’s research and development efforts.
- The company is working on developing both monoclonal antibodies and cellular therapies, leveraging advanced technologies to improve patient outcomes and long-term survival rates.
4. Contract Development and Manufacturing (CDMO):
- The CDMO segment provides essential services to biotechnology and pharmaceutical companies, capitalizing on Emergent’s robust manufacturing facilities and expertise.
- Services include process development, biologics manufacturing, and support for commercial scale-up, allowing external partners to benefit from Emergent’s manufacturing capabilities. This segment underscores Emergents role not only as a developer of its own products but also as a critical manufacturer for third-party clients in the biopharma space.
Products and Services
1. Vaccines:
- Emergent Biosolutions specializes in vaccines for a range of diseases, with a portfolio that includes:
- BioThrax: The sole anthrax vaccine approved by the FDA.
- ACAM2000: Approved smallpox vaccine.
- Ongoing development of vaccines against Zika virus, dengue fever, COVID-19, and other infectious diseases.
2. Therapeutics:
- The company develops innovative therapeutics for the treatment of infectious diseases and oncology therapies. This includes:
- Immunotherapy products targeting melanoma and non-small cell lung cancer.
- Therapeutics designed to respond to viral infections arising from current public health crises.
3. Antibodies:
- Emergent produces a range of monoclonal antibodies, which are crucial for both therapeutic and diagnostic purposes. These antibodies can target cancers and infectious disease pathogens, providing a critical tool in precision medicine.
4. Contract Development and Manufacturing Services:
- The CDMO segment supports clients by offering comprehensive development services, including:
- Process optimization, scale-up manufacturing, quality assurance, and regulatory compliance support, facilitating a complete suite of manufacturing solutions for other biotech firms.
5. Chemical, Biological, Radiological, and Nuclear (CBRN) Defense:
- The company provides medical countermeasures and advanced solutions to protect against CBRN threats. This includes specific products designed to mitigate the effects of chemical and biological attacks.
6. Public Health Preparedness:
- Emergent Biosolutions is committed to strengthening public health infrastructure by offering solutions tailored for emergency preparedness and response, ranging from pandemic readiness to specific biodefense threats.
Conclusion
Emergent Biosolutions Inc. operates through four distinct but interconnected business segments, offering a robust array of products and services designed to address the critical challenges in biodefense, infectious diseases, and oncology. Their commitment to innovation and public health preparedness positions them as a leader in the life sciences industry, dedicated to ensuring safety and health on a global scale. Through strategic partnerships and advanced development initiatives, Emergent continues to advance the science of health security, with a comprehensive focus spanning vaccines, therapeutics, contract services, and emergency preparedness solutions.
Segments
1. Biodefense:
- Emergents biodefense segment is integral in developing and deploying medical countermeasures against biological and chemical threats. This includes the advanced manufacturing and commercialization of critical vaccines and therapeutics.
- A highlight of this segment is BioThrax, the only FDA-approved vaccine for the prevention of anthrax, specifically recognized for its pivotal role in protecting the U.S. population from potential bioterrorism threats. The company also collaborates closely with government entities to ensure readiness against emerging biological threats, including collaborations under the Biomedical Advanced Research and Development Authority (BARDA) umbrella.
2. Infectious Diseases:
- This segment focuses on vaccines and treatments for various infectious diseases. Emergent Biosolutions has made significant strides in addressing public health challenges such as the Zika virus, dengue fever, Ebola virus disease, and the recent COVID-19 pandemic.
- Notable products in this domain include ACAM2000, an FDA-approved vaccine for smallpox, and ongoing efforts to develop a vaccine for COVID-19.
- In addition, the companys portfolio under development may include therapies targeting innovative solutions for pandemic and endemic infectious diseases.
3. Oncology:
- In the oncology segment, Emergent Biosolutions is dedicated to creating novel immunotherapies aimed at harnessing the body’s immune system to combat cancer effectively. The struggles against melanoma and non-small cell lung cancer are primary targets for the company’s research and development efforts.
- The company is working on developing both monoclonal antibodies and cellular therapies, leveraging advanced technologies to improve patient outcomes and long-term survival rates.
4. Contract Development and Manufacturing (CDMO):
- The CDMO segment provides essential services to biotechnology and pharmaceutical companies, capitalizing on Emergent’s robust manufacturing facilities and expertise.
- Services include process development, biologics manufacturing, and support for commercial scale-up, allowing external partners to benefit from Emergent’s manufacturing capabilities. This segment underscores Emergents role not only as a developer of its own products but also as a critical manufacturer for third-party clients in the biopharma space.
Products and Services
1. Vaccines:
- Emergent Biosolutions specializes in vaccines for a range of diseases, with a portfolio that includes:
- BioThrax: The sole anthrax vaccine approved by the FDA.
- ACAM2000: Approved smallpox vaccine.
- Ongoing development of vaccines against Zika virus, dengue fever, COVID-19, and other infectious diseases.
2. Therapeutics:
- The company develops innovative therapeutics for the treatment of infectious diseases and oncology therapies. This includes:
- Immunotherapy products targeting melanoma and non-small cell lung cancer.
- Therapeutics designed to respond to viral infections arising from current public health crises.
3. Antibodies:
- Emergent produces a range of monoclonal antibodies, which are crucial for both therapeutic and diagnostic purposes. These antibodies can target cancers and infectious disease pathogens, providing a critical tool in precision medicine.
4. Contract Development and Manufacturing Services:
- The CDMO segment supports clients by offering comprehensive development services, including:
- Process optimization, scale-up manufacturing, quality assurance, and regulatory compliance support, facilitating a complete suite of manufacturing solutions for other biotech firms.
5. Chemical, Biological, Radiological, and Nuclear (CBRN) Defense:
- The company provides medical countermeasures and advanced solutions to protect against CBRN threats. This includes specific products designed to mitigate the effects of chemical and biological attacks.
6. Public Health Preparedness:
- Emergent Biosolutions is committed to strengthening public health infrastructure by offering solutions tailored for emergency preparedness and response, ranging from pandemic readiness to specific biodefense threats.
Conclusion
Emergent Biosolutions Inc. operates through four distinct but interconnected business segments, offering a robust array of products and services designed to address the critical challenges in biodefense, infectious diseases, and oncology. Their commitment to innovation and public health preparedness positions them as a leader in the life sciences industry, dedicated to ensuring safety and health on a global scale. Through strategic partnerships and advanced development initiatives, Emergent continues to advance the science of health security, with a comprehensive focus spanning vaccines, therapeutics, contract services, and emergency preparedness solutions.